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ABSTRACT	
JAMIE	STONE:	The	Evaluation	of	AZ66,	A	Highly	Selective	Sigma-1	and	Sigma-2	Antagonist,	for	
Anticonvulsive	Effects	in	C57Bl/6	Mice	
(Under	the	direction	of	Lisa	Wilson	and	Dr.	Christopher	McCurdy)	
	
	
	
Sigma	receptors	have	become	a	popular	subject	for	research	the	past	few	decades,	but	
there	is	still	much	mystery	behind	these	receptors	and	how	they	work.	Researchers	have	found	
that	sigma	receptor	antagonists	can	attenuate	cocaine	induced	convulsions,	however,	limited	
research	has	been	conducted	on	the	effects	of	these	antagonists	on	convulsions	that	mimic	the	
types	of	seizures	associated	with	epilepsy.	Therefore,	the	aim	of	the	current	study	was	to	
evaluate	AZ66	(20	mg/kg	i.p.),	a	highly	selective	sigma	1	&	2	receptor	antagonist,	against	
pentylenetetrazole	(PTZ)	(80	mg/kg	s.c.)	induced	convulsions.		The	first	aim	of	the	study	was	to	
determine	the	optimal	dose	and	dosing	method	for	the	administration	of	PTZ	in	our	
laboratories.		Both	subcutaneous	(s.c.)	and	intraperitoneal	(i.p.)	injections	were	separately	
investigated	at	50-80	mg/kg	and	30-60	mg/kg	doses	respectively.		The	second	aim	was	to	find	
the	minimum	dose	of	AZ66	that	was	effective	at	reducing	or	attenuating	PTZ	induced	
convulsions.		The	AZ66	dose	was	administered	one	hour	before	the	PTZ	dose	administration.	
Seizure	latency	and	frequency	were	recorded.	The	subcutaneous	80	mg/kg	dose	of	PTZ	was	
chosen	due	to	its	fast	response	time	and	clear	distinction	between	seizures.		AZ66	decreased	
seizure	latency	and	increased	seizure	frequency	and	resulted	in	death	when	given	at	the	
30mg/kg	dose.		Further	studies	on	the	role	of	the	sigma	receptors	in	epilepsy	are	needed.	
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	I. Background	
Epilepsy	is	a	debilitating	disease	that	affects	over	2.4	million	adults	and	450,000	children	
in	the	United	States	alone	("Hope	Through	Research",	2016).		This	chronic	disorder	is	
recognized	by	the	World	Health	Organization	(WHO)	as	one	of	the	most	common	neurological	
diseases	worldwide	(“Epilepsy	Fact	Sheet”	2016).		Perhaps	the	most	alarming	thing	about	
epilepsy	is	that	anyone	can	develop	it	regardless	of	sex,	age,	or	ethnic	background.		Caused	by	
an	unbalance	of	hyperactive	electrical	signals	in	the	brain,	epilepsy	is	commonly	characterized	
by	unpredictable	and	frequent	seizures.			
While	epilepsy	is	a	disorder	of	multiple	seizures	over	a	period	of	time	longer	than	
twenty-four	hours,	a	seizure	is	a	single	occurrence.		Seizures	can	be	classified	into	two	broad	
categories:	generalized	and	focal/partial.		Generalized	seizures	affect	the	whole	brain	while	
focal/partial	seizures	affect	only	a	specific	part.		Generalized	seizures	are	commonly	described	
by	a	loss	of	consciousness	and	motor	control.		This	type	of	seizure	is	further	classified	into	
either	tonic-clonic,	absence,	or	atonic	seizures	depending	on	the	symptoms	that	manifest.		
Tonic-clonic	seizures,	formerly	known	as	grand	mal	seizures,	are	distinguishable	by	their	jerk-
like	contractions	of	the	whole	body	and	long	recovery	time.		This	type	of	generalized	seizure	is	
typically	long	in	duration	and	can	last	for	several	minutes.	Another	type	of	generalized	seizures	
is	the	absence	seizure,	also	known	as	the	petit	mal	seizure.	This	category	of	seizures	is	defined	
by	the	person	being	unable	to	control	his	or	her	body	position.		These	seizures	look	similar	to	
tonic	clonic	seizures,	however	the	duration	of	the	seizure	is	much	shorter	and	the	recovery	time	
is	faster.		Atonic	seizures	refer	to	generalized	seizures	in	which	the	patient’s	muscles	suddenly	
become	limp	and	unexpectedly	drop	to	the	ground.		These	seizures	are	also	referred	to	as	drop	
attacks	and	often	result	in	injury	(“Types	of	Seizures”,	2016).	
	Unlike	generalized	seizures,	in	focal/partial	seizures	consciousness	is	not	lost	and	the	
region	of	the	brain	affected	is	limited	to	a	particular	area.		The	affected	area	of	the	brain	
determines	the	classification	of	the	simple	partial	seizure	as	well	as	the	manifestation	of	the	
symptoms.		These	seizures	can	affect	specific	motor	functions,	blood	pressure	and	heart	rate,	
parts	of	the	brain	that	trigger	emotions,	and	result	in	sensory	hallucinations.		Often	times,	a	
simple	partial	seizure	will	start	in	one	area	of	the	brain	and	move	to	another;	this	results	in	a	
complex	partial	seizure.		This	type	of	seizure	is	distinguished	by	an	altered	state	of	
consciousness	not	seen	in	simple	partial	seizures.		People	diagnosed	with	complex	partial	
seizures	report	experiencing	staring	blankly	into	space	or	performing	repetitive,	non-purposeful	
tasks.		As	a	whole,	epilepsy	displays	a	distinct	combination	of	seizures	specific	to	the	individual	
patient	(“Types	of	Seizures”,	2016).		This	makes	each	disease	unique	to	the	individual	and	
oftentimes	creates	difficulties	in	diagnosing	and	treating	epilepsy.	
The	National	Institute	of	Neurological	Disorders	and	Stroke	(NINDS)	considers	a	person	
to	be	epileptic	if	they	have	two	or	more	seizures	occurring	over	a	time	period	longer	than	
twenty-four	hours	("Hope	Through	Research",	2016).		There	are	many	individualized	aspects	to	
epilepsy	including	the	cause,	type,	and	severity	of	the	seizures	that	contribute	to	the	specificity	
of	the	disease.		It	is	imperative	to	understand	and	consider	these	aspects	when	determining	the	
appropriate	treatment	plan.	In	the	book	The	Epilepsies:	Seizures,	Syndromes	and	Management,	
Panayiotopoulos	highlights	3	important	diagnostic	steps	that	doctors	follow	in	order	to	
determine	the	correct	therapy	(Panayiotopoulos	2005).		First,	it	is	important	to	know	that	the	
seizures	are	not	a	result	of	an	underlying,	curable	illness.		Seizures	can	be	caused	by	a	number	
of	disorders	including	a	high	fever,	a	buildup	of	toxins,	abnormal	glucose	levels,	or	a	brain	
infection	(Shelat,	2015).		If	a	patient	is	incorrectly	diagnosed	with	epilepsy,	then	they	are	being	
denied	lifesaving	medical	care.		As	a	result,	doctors	need	to	exhaust	all	diagnostic	tests	before	
concluding	that	a	person	has	epilepsy.		If	the	seizures	are	determined	to	be	caused	by	epilepsy,	
doctors	then	ascertain	the	type	of	seizures	being	presented.		This	step	ensures	later	on	that	the	
treatment	selected	will	be	tailored	for	the	individual	patient.		Finally,	after	the	type	of	seizure	is	
established,	then	the	epileptic	syndrome	can	be	diagnosed.		This	ensures	an	accurate	and	
personalized	treatment	for	each	patient.		Currently,	there	is	no	cure	for	epilepsy	but	it	can	be	
controlled	with	medication	and	other	lifestyle	changes.		About	50%	of	seizures	are	completely	
controlled	using	anti-epileptic	drugs	(AEDs)	and	an	additional	25%	of	patients	drastically	
improve	(Goldenberg	MM,	2010).		Along	with	medication,	doctors	also	implement	lifestyle	
changes	such	as	diet	and	exercise	as	part	of	a	holistic	treatment	plan.		The	goal	is	to	prevent	
seizures	and	improve	the	patient’s	quality	of	life.	
As	of	now,	there	are	only	26	anti-epileptic	drugs	currently	on	the	market.		These	drugs	
produce	a	host	of	side	effects	that	range	from	drowsiness	to	a	loss	of	coordination	or	memory,	
and	even	death	("List	of	Anti-Epileptic	Drugs",	2014).	In	order	to	generate	new	antiepileptic	
medications,	NINDS	created	a	program	that	tests	compounds	for	anti-seizure	activity	called	the	
Epilepsy	Therapy	Screening	Program	(ETSP)	formerly	called	the	Anticonvulsant	Screening	
Program	(ASP).		One	of	the	main	focuses	of	this	program	is	to	identify	potential	therapeutic	
agents	that	could	be	used	to	treat	epilepsy	("Epilepsy	Therapy	Screening	Program"	2017).	
When	a	compound	is	submitted	to	the	ETSP,	its	structure	is	compared	to	a	large	internal	
database	to	help	determine	any	structure-activity	relationships	and	to	ensure	that	the	
compound	is	chemically	unique.		NINDS	uses	well	established	rodent	seizure	models	to	screen	
in	four	categories:	Standard	Anti-Ictal	Screening,	Models	of	Pharmacoresistance,	
Identification/Differentiation,	and	Screening	for	Related	Indications.		These	four	areas	test	the	
compound’s	efficacy	in	treating	specific	seizure	types,	determining	its	effect	on	the	seizure	
thresholds,	and	if	treats	related	medical	comorbidities.		
The	Maximal	Electric	Shock	(MES)	is	a	standard	Anti-Ictal	Screening	model	used	to	mimic	
generalized	tonic-clonic	seizures.		This	type	of	test	involves	an	electric	shock	to	see	if	the	
compound	will	prevent	the	seizure	from	occurring	when	all	neuronal	circuits	in	the	brain	are	
maximally	active.		In	order	to	test	a	substance’s	ability	to	treat	complex	partial	seizures,	the	
Kindled	Rat	Model	is	employed.	This	model	can	also	be	modified	to	include	a	simulation	of	
pharmacoresistance.		About	30%	of	epileptic	patients	are	resistant	to	traditional	anti-seizure	
drugs	(Brodie,	Kwan,	2002),	so	this	analysis	is	a	useful	way	to	identify	compounds	that	
demonstrate	an	ability	to	treat	therapy	resistant	epilepsies.		Classified	under	
Identification/Differentiation,	the	Intravenous	Pentylenetetrazole	(Metrazol,	PTZ)	Seizure	
Threshold	Test	determines	the	compounds	ability	to	change	the	seizure	threshold.	PTZ	is	
intravenously	injected	into	the	rat	to	produce	a	chemically	induced	seizure.		If	the	compound	
lowers	the	seizure	threshold,	then	it	is	considered	to	be	pro-convulsant	because	the	number	of	
seizures	increases.		Likewise,	if	the	compound	decreases	the	number	of	seizures	it	is	an	
anticonvulsant	because	the	substance	raised	the	seizure	threshold.		The	Intravenous	PTZ	
Seizure	Threshold	Test	is	a	staple	in	testing	potential	new	anti-seizure	medications	because	it	
quickly	identifies	if	the	compound	is	counter-effective.		Finally,	the	Mouse	Formalin	Test	of	
Hyperalgesia	screens	for	a	substance’s	ability	to	also	treat	pain	related	to	epilepsy.		This	
particular	model	determines	if	the	compound	being	tested	reduces	acute	and	inflammatory	
pain	in	the	mouse.		This	test	is	important	because	patients,	in	addition	to	having	seizures,	often	
have	to	deal	with	the	comorbidities	of	epilepsy	or	the	side	effects	of	the	treatment	that	affect	
their	quality	of	life	(Kerr,	2012).			
Due	to	the	numerous	side	effects	and	the	limited	number	of	drugs	on	the	market,	many	
patients	are	seeking	alternative	forms	of	therapies.	These	alternative	therapies	are	often	used	a	
last	resort	when	approved	forms	of	medication	fail.		Among	these	alternative	therapies	“herbal	
remedies	are	used	as	first	line	treatments	for	all	illnesses	in	an	estimated	80%	of	the	world’s	
population”	(Kneen,	Appleton,	2006).		Unfortunately,	these	nonconventional	AEDs	are	further	
encouraged	by	the	media	with	little	or	no	evidence	based	support	and	require	further	
investigation	to	determine	the	effectiveness	of	such	treatment	plans.		
One	such	alternative	treatment	for	epilepsy	is	marijuana,	also	known	as	cannabis.	
Specifically,	there	are	two	compounds	of	interest	in	marijuana:	cannabidiol	(CBD)	and	
tetrahydrocannabinol	(THC).		These	two	compounds	are	both	known	for	their	anti-convulsant	
effects	in	the	MES	model	of	epilepsy,	but	only	THC	exerts	its	effects	through	the	
endocannabinoid	system.		CBD’s	mechanism	of	action	is	still	unclear.		Interestingly,	CBD	and	
THC	are	suggested	to	have	a	synergistic	relationship	in	their	anticonvulsant	properties	due	to	
CBD’s	mechanisms	of	action	(Szaflarski	et	al.,	2014).		The	ratio	of	CBD	to	THC	may	determine	
the	effectiveness	of	treating	seizures	while	minimizing	the	psychoactive	effects	associated	with	
marijuana.		One	study	found	that	cannabis	containing	high	concentrations	of	CBD	and	low	
concentrations	of	tetrahydrocannabinol	(THC)	was	very	effective	as	an	anticonvulsant	in	animal	
models	(Szaflarski	et	al.,	2014).		While	medical	marijuana	use	has	been	dated	back	to	China	
approximately	2500	BC	(Jiang	et	al.,	2006),	there	is	only	circumstantial	evidence	of	its	
effectiveness	to	treat	epilepsy	because	it	is	still	unclear	how	marijuana	exerts	its	anti-epileptic	
properties	(Szaflarski	et	al.,	2014).	Nevertheless,	cannabidiol	has	recently	gained	popularity	
with	the	general	public	as	a	potential	medication	for	drug	resistant	epilepsies.		Capitalizing	on	
this	popularity,	GW	Pharmaceuticals	announced	a	new	experimental	drug	that,	if	approved	by	
the	Food	and	Drug	Administration	(FDA),	will	be	the	first	marijuana	based	prescription	drug	in	
the	United	States	(Pollack,	2016).		Epidiolex	contains	cannabidiol	and	is	currently	showing	
promising	results	in	treating	Dravet	Syndrome	during	phase	3	clinical	trials	(Pollack,	2016).		
During	this	phase,	the	effectiveness	of	the	drug	is	statistically	calculated	against	a	placebo.		
After	undergoing	multiple	tests,	the	FDA	can	then	decide	whether	or	not	to	approve	the	drug	
for	sale.	Dravet	syndrome	is	a	childhood	epilepsy	known	for	its	resistance	to	drug	therapy.		If	
Epidiolex	is	approved	by	the	FDA,	it	could	prove	to	be	a	major	breakthrough	in	treating	
intractable	epilepsies.		While	the	results	of	this	trial	look	promising,	it	is	still	unknown	how	
cannabidiol	exerts	its	antiepileptic	properties	or	its	long	term	effects.	
Because	CBD	is	a	schedule	1	drug,	illegal	due	to	its	high	potential	for	abuse,	no	currently	
accepted	medical	use,	and	safety	concerns,	it	is	important	to	seek	alternative	treatments	for	
epilepsy.		Sigma	receptors	could	prove	to	be	that	alternative	treatment.		Sigma	receptors	were	
once	thought	to	be	a	class	of	opioids	receptors	due	to	the	initial	compounds	that	had	opioid-
like	effects	and	unique	effects	that	could	not	be	reversed	by	standard	opioid	antagonists	
(Martin,	1976).		However,	it	was	later	proven	to	be	a	separate	class	of	receptors	with	a	selective	
drug	pattern	and	distinct	anatomical	distribution.		For	example,	sigma	receptors	have	a	high	
affinity	for	(+)	benzomorphans,	whereas	opioid	receptors	selectively	prefer	(-)	benzomorphans,	
and	were	found	to	produce	effects	unaffected	by	opioid	antagonists.		Sigma	receptors	interact	
with	a	diverse	set	of	compounds	including	opiates,	neuroleptics,	antihistamines,	and	
antidepressants.		There	are	two	distinct	subtypes	of	sigma	receptors.	Sigma-1	receptors	are	
expressed	more	dominantly	over	sigma-2	and	are	slightly	larger	in	size.		Sigma-1	receptors	are	
also	known	to	translocate	during	signaling	and	are	associated	with	regulating	intracellular	
secondary	messengers.		So	far,	only	the	sigma-1	receptor	has	been	sequenced	and	cloned	from	
a	variety	of	different	species,	including	humans.		The	identity	of	the	sigma-2	receptor	is	still	
unknown	and	is	under	current	debate.		However,	there	is	strong	evidence	that	the	sigma-2	
receptor	is	a	unique	protein	that	resides	in	lipid	rafts	(Chu,	et	al.	2015).	Currently,	we	do	not	
know	of	any	purely	selective	sigma-2	compounds.		Sigma	compounds	that	interact	with	
receptors	either	non-selectively	bind	with	either	sigma-1	or	sigma-2,	or	solely	sigma-1	
receptors.		The	sigma	agonists	and	antagonist	that	are	frequently	utilized	in	research	and	have	
a	higher	affinity	for	sigma-2	receptors	(over	sigma-1	receptors)	also	bind	with	opioid	receptors.		
Sigma	receptors	as	a	whole	are	found	throughout	the	body.		The	highest	concentration	of	sigma	
receptors	is	found	in	the	brain	and	spinal	cord,	most	notably	in	the	brainstem	motor	nuclei.		
This	suggests	that	sigma	receptors	play	a	significant	role	in	motor	function	and	control.		Sigma	
receptors	are	also	found	throughout	the	body	in	peripheral	organs	suggesting	that	perform	a	
necessary	physiological	function	(Matsumoto	et	al.,	2007).		Because	of	their	widespread	
distribution	and	concentration	in	motor	nuclei,	sigma	receptors	represent	a	potential	target	
towards	creating	new	medicines	and	in	treating	numerous	diseases,	including	epilepsy	
(Maurice,	Su,	2009).	
		
	
	
	
	
	
Figure	1:	Structure	of	AZ66	
AZ66	{3-[4-(4-cyclohexylpiperazin-1-yl)pentyl]-6-fluorobenzo[d]	thiazole-2(3H)-one}	is	a	
highly	selective	sigma-1	and	sigma-2	receptor	antagonist	that	binds	with	almost	equal	affinity	
to	each	subtype.		This	synthetic	compound	was	derived	from	CM156,	also	a	sigma	receptor	
antagonist.		AZ66	was	developed	for	its	longer	half-life	and	an	increased	metabolic	stability	
than	its	precursor	CM156.		AZ66	has	a	favorable	pharmacokinetic	profile	and	is	capable	of	being	
administered	orally.		This	novel	ligand	has	been	shown	to	mitigate	many	methamphetamine-
induced	behaviors	(Seminerio	et	al.,	2016)	as	well	as	attenuate	cocaine	induced	seizures	
(Matsumoto	et	al,	2002).		Because	of	these	properties,	it	is	reasonable	to	assume	that	AZ66	
could	also	be	effective	in	reducing	seizures	produced	by	epilepsy.		Until	now,	there	have	not	
been	any	studies	to	determine	the	effects	of	AZ66	on	seizures	that	mimic	epilepsy.		This	opens	
a	whole	new	area	of	investigation	for	sigma	receptor	antagonists	like	AZ66.			
This	thesis	aims	to	begin	that	exploration	by	studying	AZ66’s	anticonvulsive	effects	in	PTZ	
induced	seizures	that	mimic	epilepsy.		PTZ	is	a	GABAA	receptor	antagonist	that	is	the	gold	
standard	for	chemically	inducing	seizures	in	anti-epileptic	drug	assessments	(Lüttjohann,	
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Fabene,	&	Luijtelaar,	2009).		To	perform	this	evaluation,	the	optimal	dose	and	dosing	method	of	
PTZ	in	our	laboratories	needed	to	be	assessed.		From	there,	the	minimum	dose	of	AZ66	
effective	at	reducing	PTZ	induced	seizures	can	then	be	determined.			
	
II. Methods	
Subjects	
	 Adult	male	black	C57BL6	mice	were	acquired	from	Harlan	Laboratories	and	were	the	
subjects	to	complete	the	2	aims.		All	animals	were	housed	5	to	a	cage	and	received	food	and	
water	ad	lib.		The	housing	facilities	were	maintained	on	a	12-hour	light	schedule	from	6:00am	
to	6:00	pm.		The	Institutional	Animal	Care	and	Use	Committee	(IACUC)	approved	the	methods	
performed	in	this	study.	
Drug	Preparation	
	 All	drugs	were	dissolved	in	saline	solution	before	administration.		AZ66	was	prepared	
and	synthesized	in	Dr.	McCurdy’s	lab	as	part	of	the	Department	of	BioMolecular	Sciences	
Division	of	Medicinal	Chemistry.		Drugs	were	delivered	to	the	animals	by	either	intraperitoneal	
(i.p,)	or	subcutaneous	(s.c.)	injection.	
Aim	1	
	 In	order	to	find	the	optimal	dosing	method	and	dose	of	pentylenetetrazole	(PTZ),	8	mice	
for	each	dose	and	dosing	method	were	brought	into	the	procedure	room	to	acclimate	for	30	
minutes.		Afterwards	the	first	mouse	was	injected	with	a	single	dose	of	PTZ,	dissolved	in	normal	
saline,	and	placed	into	a	Plexiglas	chamber.		There	were	no	more	than	2	mice	in	each	Plexiglas	
chamber	at	one	time.		Normal	saline	was	used	as	a	negative	control.		Each	mouse	was	observed	
for	a	total	time	of	30	minutes,	during	which	we	watched	for	the	appearance	of	tonic-clonic	
seizures.		Tonic-clonic	seizures	are	characterized	by	the	stiffening	of	the	body	followed	by	
spasms	and	jerks	of	the	muscles.		The	latency	period	of	the	first	major	seizure	and	the	number	
of	mini	and	major	seizures	that	each	mouse	had	was	recorded.		We	defined	major	seizures	as	
having	very	visible	tonic-clonic	seizures	and	a	slow	recovery	time	afterwards,	usually	around	the	
minute	mark	or	longer	depending	on	the	severity	of	the	seizure.		While	mini	seizures	were	
defined	as	very	short,	rapid	convulsions	in	which	the	tonic-clonic	seizure	was	difficult	to	
observe	and	the	mice	had	a	very	rapid	recovery	of	a	few	seconds.	
Aim	2		
After	a	30	min	acclamation	period,	during	which	the	mice	were	weighed	and	marked,	
the	AZ66	compound	was	administered	at	either	a	10,	20,	or	30	mg/kg	dose.		After	an	hour	
pretreatment	of	the	AZ66,	the	mice	were	then	treated	with	a	subcutaneous	80	mg/kg	dose	of	
PTZ.		Then,	as	before	in	the	dose	response,	the	mice	were	then	observed	for	30	minutes	and	
the	seizure	latency	and	the	number	of	mini	and	major	seizures	recorded.	
Data	Analysis	
	 Data	was	shown	as	mean	±	SEM.	with	each	group	having	n=	8	animals.	Statistical	
analysis	was	performed	using	one-way	ANOVA	preceded	by	the	Tukey	post	hoc	test	to	define	
the	significant	different	against	the	vehicle	control	at	p<.05	for	each	dose	of	PTZ	and	AZ66.	
	
	
	
	
	III. Results	
Aim	1	
Figure	2	demonstrates	the	seizure	latency	for	two	dosing	methods,	intraperitoneal	and	
subcutaneous,	at	increasing	doses	of	PTZ.		The	saline	solution	as	expected	did	not	produce	a	
seizure	and	therefore	had	a	latency	time	of	30	minutes	which	was	the	total	time	of	observation.		
Every	dose	for	each	dosing	method	was	significantly	different	when	compared	to	the	vehicle	
with	the	exception	of	the	intraperitoneal	30	mg/kg	dose.		The	i.p.	40	mg/kg	dose	of	PTZ	differed	
from	the	vehicle	at	a	p-value	<.005	while	the	other	doses,	with	the	exception	of	the	i.p.	30	
mg/kg	dose	of	PTZ,	were	significantly	different	with	p-values	<	.001.		The	dosing	methods	only	
significantly	differed	between	the	s.c.	50	mg/kg	dose	compared	to	the	i.p.	30	mg/kg	dose	and	
the	60	mg/kg	dose	s.c.	matched	to	the	i.p.	40	mg/kg	dose	of	PTZ	(p<.001).		The	fastest	latency	
time	was	60	mg/kg	dose	of	PTZ	administered	intraperitoneally.	
	
	Figure	2:	Seizure	latency	of	intraperitoneal	and	subcutaneous	dosing	of	PTZ	
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	Figure	3:	Average	number	of	total	seizures	induced	by	each	dose	of	PTZ	
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Figure	4:	Average	number	of	major	seizures	for	intraperitoneal	and	subcutaneous	dosing	of	PTZ	
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Figure	3	represents	the	total	number	of	seizures	for	each	dose	of	PTZ	and	Figure	4	is	the	
average	number	of	major	seizures	for	each	dosing	method	and	the	dose	studied.		The	70	mg/kg	
dose	administered	subcutaneously	and	the	60	mg/kg	dose	administered	intraperitoneally	
differed	significantly	from	the	vehicle	at	a	95%	confidence	interval.		There	was	no	significant	
difference	between	the	dosing	methods	and	the	number	of	seizures	for	each	comparison	
group.		Both	figures	3-4	reflect	that	the	80	mg/kg	subcutaneous	dose	of	PTZ	induced	the	most	
seizures	although	the	intraperitoneal	60	mg/kg	dose	was	statistically	comparable.	
Aim	2	
AZ66	did	not	produce	any	seizures	or	adverse	side	effects	during	the	hour	pretreatment.		
Figure	5	relates	the	average	seizure	latency	time	of	the	different	doses	of	AZ66	compared	to	
the	lone	80	mg/kg	dose	of	PTZ.		All	doses	of	AZ66	were	statistically	significant	at	a	p-value	<	
.001	when	compared	to	the	vehicle.		As	the	dose	of	AZ66	increased,	the	onset	of	the	seizures	
occurred	more	rapidly.		While	conducting	the	trial	with	the	pretreatment	of	the	30	mg/kg	dose	
of	AZ66,	the	experiment	was	stopped	early	when	it	became	apparent	that	inducing	a	seizure	
was	fatal	at	this	dose.	
Figure	5:	Average	seizure	latency	time	for	doses	of	AZ66	
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	Figure	6:	Average	number	of	total	seizures	for	each	dose	of	AZ66	with	PTZ	(80mg/kg	s.c.)	
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Figure	7:	Average	number	of	major	seizures	for	doses	of	AZ66	with	PTZ	(80mg/kg	s.c.)	
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Figures	6	and	7	represent	the	dose	response	of	AZ66	on	the	number	of	chemically	induced	
seizures.		In	figure	6,	all	groups	were	significantly	different	at	a	p-value	of	.001	when	compared	
to	the	vehicle.		When	compared	to	the	lone	dose	of	80	mg/kg	subcutaneous	dose	of	PTZ,	only	
the	highest	dose	of	AZ66	(30	mg/kg)	proved	to	be	significant	(p<.001).	Figure	7	demonstrates	
the	effects	of	increasing	the	dose	of	AZ66	on	the	number	of	major	seizures.		All	doses	of	AZ66	
differed	from	the	vehicle	at	a	p-value	<	.05.		When	the	number	of	major	seizures	produced	
when	pretreated	with	AZ66	was	compared	to	the	lone	dose	of	the	s.c.	80	mg/kg	dose	of	PTZ,	
the	20	mg/kg	and	the	30	mg/kg	proved	to	be	significantly	different	(p<.05).		Both	of	these	
graphs	illustrate	that	as	the	dose	of	AZ66	increased	so	did	the	frequency	of	the	seizures	
increased.			
	
IV. Discussion	
The	subcutaneous	80mg/kg	dose	of	PTZ	was	chosen	due	to	the	quick	response	time,	
frequency	of	the	seizures,	and	the	clear	distinctions	between	mini	and	major	seizures.		
However,	the	effects	of	AZ66	were	the	opposite	of	what	we	expected.		When	screening	AZ66,	
the	compound	actually	decreased	the	seizure	latency	time	while	increased	the	number	of	
seizures	as	the	dose	increased.		These	seizures	were	more	violent	and	resulted	in	death	at	the	
30	mg/kg	dose	of	AZ66.			
While	AZ66	may	attenuate	seizures	induced	by	cocaine,	it	does	not	do	so	for	PTZ	induced	
seizures.		PTZ	exerts	its	effects	by	acting	as	a	GABAa	receptor	antagonist.		GABA	is	one	the	most	
important	inhibitory	neurotransmitters	in	the	central	nervous	system	(Heard,	Palmer,	&	
Zahniser	2008)	and	is	the	target	of	many	AEDs.		Because	AZ66	did	not	perform	as	expected,	it	is	
reasonable	to	assume	that	AZ66	does	not	directly	act	on	the	GABA	pathway.		This	is	consistent	
with	the	fact	that	cocaine	indirectly	induces	its	effects	on	GABA	receptors	through	
neurotransmitters	(Centonze,	et	al.,	2002).		It	is	likely	that	sigma	antagonists	are	not	be	
effective	in	treating	GABA-mediated,	chemically	induced	seizures.		This	assumption	is	
supported	by	the	fact	that	AZ66	is	effective	at	reducing	seizures	induced	by	cocaine,	but	not	
seizures	induced	by	PTZ.		However,	because	cocaine	induced	seizures	are	drug	refractory,	AZ66	
could	still	prove	useful	in	other	types	of	epilepsy.		
	
V. Future	Studies	
	 Futures	studies	for	this	project	are	needed.		First	off,	AZ66	needs	to	be	tested	for	
efficacy	in	reducing	electrically	induced	seizures	using	the	Maximal	Electroshock	seizure	test.		It	
is	necessary	to	perform	this	test	to	rule	out	the	possibility	of	AZ66’s	antiepileptic	effects	in	a	
different	seizure	type.		While	AZ66	is	not	effective	in	attenuating	seizures	caused	by	chemical	
stimulation,	it	may	be	beneficiary	in	electrically	kindled	seizures.		From	there,	PTZ	and	MES	
induced	convulsion	tests	should	be	run	on	selective	antagonists	for	both	sigma	1	and	sigma	2	
receptors	to	find	which	is	responsible	for	the	increase	of	the	convulsions	seen	when	using	the	
non-selective	sigma	antagonist	AZ66.	
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